Debra Rushton Ellis

US Patent:

20090156537, Jun 18, 2009

Filed:

Oct 24, 2008

Appl. No.:

12/257852

Inventors:

Michael R. Bowman - Westwood MA, US
Maximilliam T. Follettie - Belmont MA, US
Hang Chen - Framingham MA, US
Cara Williams - Methuen MA, US
Aaron Winkler - Arlington MA, US
Debra Ellis - Lowell MA, US
Wei Liu - Lexington MA, US

Assignee:

Wyeth - Madison NJ

International Classification:

A61K 31/7105
A61P 11/06
A61P 11/00
A61K 31/198

US Classification:

514 44, 514564

Abstract:

The present invention provides compositions and methods useful for detecting or treating asthma or other allergic or inflammatory diseases. In one aspect, the methods of the present invention include inhibiting the activity or expression of a component of an arginine metabolic pathway in tissues affected by asthma or other allergic or inflammatory diseases. In many embodiments, the component being inhibited is a cationic amino acid transporter, an arginase, or a component downstream of the arginase. In many other embodiments, the activity or expression of the component is inhibited by an agent that binds to the component. In still many other embodiments, the activity or expression of the component is inhibited by an agent that binds a polynucleotide encoding the component.

US Patent:

20040234517, Nov 25, 2004

Filed:

Mar 4, 2004

Appl. No.:

10/792280

Inventors:

Michael Bowman - Westwood MA, US
Maximillian Follettie - Belmont MA, US
Hang Chen - Newton MA, US
Cara Williams - Methuen MA, US
Aaron Winkler - Arlington MA, US
Debra Ellis - Lowell MA, US
Wei Liu - Sudbury MA, US

Assignee:

WYETH - Madison NJ

International Classification:

A61K038/48
A61K048/00

US Classification:

424/094630, 514/044000, 514/565000

Abstract:

The present invention provides compositions and methods useful for detecting or treating asthma or other allergic or inflammatory diseases. In one aspect, the methods of the present invention include inhibiting the activity or expression of a component of an arginine metabolic pathway in tissues affected by asthma or other allergic or inflammatory diseases. In many embodiments, the component being inhibited is a cationic amino acid transporter, an arginase, or a component downstream of the arginase. In many other embodiments, the activity or expression of the component is inhibited by an agent that binds to the component. In still many other embodiments, the activity or expression of the component is inhibited by an agent that binds a polynucleotide encoding the component.